Better Compliance Through Technology
In the clinical trials arena, integrated software solutions help life science companies meet ever more stringent compliance challenges.
Articles in this issue
Analytical Instrument Qualification
GMP and Phase I Clinical Trials: Streamlining the Critical Path?
Team Effort
Rated PG: Pharmaceutical Guidance Suggested
European Clinical Trial Regulations Undergo a Slow Revolution
A Practical and Cost-Effective Risk Assessment for the Validation of Commercial Laboratory Computerized Systems
Moving Biotech Products from CBER to CDER: A Work in Progress
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chief
New Climate
2006: A Regulatory Odyssey
CDER?s Division of Post-Marketing Evaluation for Quality Assessment
Better Compliance Through Technology
Good Clinical Practice Q&A
Keeping Pace
The Growing Regulatory Burden and Revolution in Global Clinical Trials
Recent Videos
Related Content
The Benefits of DBS-GC–MS/MS in Barbiturate Detection
December 5th 2024Article
Three analytical and two pre-treatment methods—gas chromatography–mass spectrometry (GC–MS), gas chromatography–tandem mass spectrometry (GC–MS/MS), and liquid chromatography–tandem mass spectrometry (LC–MS/MS) plus liquid-liquid extraction (LLE) and dried blood spot (DBS) —were compared for the quantitation and characterization of barbiturates.
Juby Mathew;Leslie P. Silva;Chad Bastian;Christopher Williams;Alyssa McBurney;Mark J. Perkins;Vaughan S. Langford
November 11th 2024Article
Pharmaceutical excipients, such as polyethylene glycol-based polymers, must be tested for the presence of ethylene oxide (EtO) and 1,4-dioxane as part of a safety assessment, according to USP Chapter <228>.
